Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CRI-2021-02 | Other Identifier | CHU de Québec - Université Laval |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Meridian Bioscience, Inc. | INDUSTRY |
| Ministère de l'Économie, de la Science et de l'Innovation | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Acute respiratory infections (such as influenza-like illness and upper respiratory tract infection) and acute infectious diarrhea are, for the most part, conditions that do not require medical management or specific treatment. Depending on the level of their transmission in the community, however, these diseases place significant clinical and financial burden on the healthcare system, particularly on emergency departments (ED). The investigators propose a prospective multicenter cohort study with which they aim to validate clinical decision rules combining 1) rapid molecular tests and 2) risk stratification tools to identify patients at low risk for complications related to acute respiratory infection and acute infectious diarrhea. The use of these clinical decision rules by nurses in ED triage could allow low-risk patients to be sent directly home for self-treatment without having to see the emergency physician. By eliminating the need for physician assessment, paraclinical testing and prolonged waiting in the ED, these triage-based clinical decision rules could provide a new, safe care pathway for acute respiratory infections and acute infectious diarrhea, reducing the burden on the patient, the healthcare system, and society.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Acute respiratory infections | Participants will be recruited according to their symptoms when presenting to the emergency room. They can be included either in the acute respiratory infection group or acute infectious diarrhea group or both. Immediately after triage, eligible patients will be approached by research personnel (nurse or other professional authorized to perform the sampling and techniques required for the study) and enrolled after consent has been obtained. Once the study procedures are completed, participants will follow the care pathway that they would normally follow without the research project. The results of the clinical decision rule (molecular test and risk stratification tool) will not be disclosed to the treating team or the patient. | ||
| Acute infectious diarrhea | Participants will be recruited according to their symptoms when presenting to the emergency room. They can be included either in the acute respiratory infection group or acute infectious diarrhea group or both. Immediately after triage, eligible patients will be approached by research personnel (nurse or other professional authorized to perform the sampling and techniques required for the study) and enrolled after consent has been obtained. Once the study procedures are completed, participants will follow the care pathway that they would normally follow without the research project. The results of the clinical decision rule (molecular test and risk stratification tool) will not be disclosed to the treating team or the patient. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| 7- and 30-day combined incidence of ED returns, hospitalizations, and deaths. | Combined proportion incidence at 7 and 30 days after the initial visit of ED returns, hospitalizations and deaths related to acute respiratory infection or acute infectious diarrhea (obtained from provincial administrative databases). | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence proportion of ED returns | Incidence proportion of ED returns at 7 and 30 days after the initial visit. | 30 days |
| Incidence of prescribing antiviral medication | Incidence of prescribing antiviral medication (e.g., oseltamivir) at the initial ED visit and at 7 days (telephone follow-up). |
Not provided
Acute Respiratory Infections :
Inclusion Criteria:
Exclusion Criteria:
Acute infectious diarrhea :
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Participants will be recruited according to their symptoms when presenting to the ED. They can be included in the acute respiratory infection group, the acute infectious diarrhea group or both.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre hospitalier universitaire de Montréal | Montreal | Quebec | H2X 0A9 | Canada | ||
| Hôpital Général Juif |
Not provided
Not provided
Not provided
Not provided
Nasopharyngeal swab samples and rectal swab samples
| 7 days |
| Incidence of antibiotic prescribing | Incidence of antibiotic prescribing at initial visit and at 7 days (telephone follow-up). | 7 days |
| Incidence of intensive care unit admission | Incidence of intensive care unit admission at 30 days (obtained from provincial administrative database on hospital admissions). | 30 days |
| Mean costs of care of the initial ED visit from a health system perspective | Mean costs of the initial ED visit from a health system perspective estimated using time-driven activity-based costing (data obtained from initial visit data collection, electronic medical records and provincial physician billing database). | 30 days |
| Mean costs of the disease from the patient perspective | Mean 7-day costs from the patient perspective (obtained from the Cost for Patient Questionnaire - the CoPaQ- administered at telephone follow-up). | 7 days |
| Length of stay in the ED | Length of stay in the ED on the initial visit (electronic medical records). | Measured from ED arrival to ED discharge on the initial visit (maximum 120 hours) |
| Incidence proportion of hospitalizations | Incidence proportion of hospitalizations at 7 and 30 days after the initial visit. | 30 days |
| Incidence proportion of deaths | Incidence proportion of deaths at 7 and 30 days after the initial visit. | 30 days |
| Montreal |
| Quebec |
| H3T 1E2 |
| Canada |
| CHU de Québec - Université Laval | Québec | G1V 4G2 | Canada |